1. Home
  2. SN vs JAZZ Comparison

SN vs JAZZ Comparison

Compare SN & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SharkNinja Inc.

SN

SharkNinja Inc.

HOLD

Current Price

$101.20

Market Cap

12.4B

Sector

N/A

ML Signal

HOLD

Logo Jazz Pharmaceuticals plc (Ireland)

JAZZ

Jazz Pharmaceuticals plc (Ireland)

HOLD

Current Price

$173.33

Market Cap

10.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SN
JAZZ
Founded
1993
2003
Country
United States
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.4B
10.8B
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
SN
JAZZ
Price
$101.20
$173.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
15
Target Price
$126.29
$194.40
AVG Volume (30 Days)
2.3M
1.5M
Earning Date
11-06-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
58.74
N/A
EPS
4.05
N/A
Revenue
$6,084,941,000.00
$4,157,832,999.00
Revenue This Year
$18.26
$5.80
Revenue Next Year
$11.75
$6.06
P/E Ratio
$25.03
N/A
Revenue Growth
18.87
4.14
52 Week Low
$60.50
$95.49
52 Week High
$128.51
$182.99

Technical Indicators

Market Signals
Indicator
SN
JAZZ
Relative Strength Index (RSI) 64.21 66.05
Support Level $83.21 $172.19
Resistance Level $90.53 $182.75
Average True Range (ATR) 4.20 6.09
MACD 1.75 1.42
Stochastic Oscillator 96.49 77.50

Price Performance

Historical Comparison
SN
JAZZ

About SN SharkNinja Inc.

SharkNinja Inc is a product design and technology company that creates 5-star-rated lifestyle solutions through inventive products for consumers around the world. Its product categories include Cleaning, Cooking, Food Preparation, Home Environment and Beauty products. It sells vacuum cleaners, cooking pots, fryers, hair dryers, etc. The SharkNinja Group is expected to carry on the design, production, marketing, and distribution of the Shark and Ninja brands of small household appliances in North America, Europe and other selected international markets (excluding the Asia Pacific Region and Greater China). Currently, the majority of the revenue is derived from the U.S. market.

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Share on Social Networks: